Stockwinners Market Radar for March 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 288.2K shares of Coinbase today

18:50 EDT McCormick CEO: The cost environment is a challenge - In an interview on CNBC's Mad Money, Lawrence Kurzius said "increased costs have to make their way to the consumer."

17:55 EDT VLNS Stock trading resumes

17:20 EDT Vir Biotechnology to replace Matador in S&P 600 at open on 4/4

17:18 EDT Camden Property to replace People's United in S&P 500 at open on 4/4 - M&T Bank (MTB) is acquiring People's United Financial (PBCT) in a deal expected to be completed on or about April 4.

17:01 EDT Kinross Gold plans to divest Russian assets - Kinross Gold Corporation provided an update regarding its activities in Russia. Subsequent to Kinross' disclosure on March 2, the company has been developing a transition plan to divest its Russian assets. Kinross has received a number of unsolicited proposals regarding its Russian business and is now in exclusive negotiations with a third-party mining company regarding a potential sale of 100% of its assets in the country. Any such divesture or change of control would be subject to Russian government approval. As part of the exclusivity agreement and to properly maintain assets pending a change of control, the company's Russian subsidiaries are continuing to operate during the transition period. Kinross will also continue to manage and mitigate the environmental impacts of its operations.

16:58 EDT Lululemon jumps 7% to $369.33 after FY22 guidance beats estimates

16:50 EDT Micron expects both DRAM, NAND gross margins to increase sequentially in Q3 - Sees Q3 gross margin 48% +/- 1%. Sees Q3 operating expenses $1.05B +/- $25M. Says improved fiscal year financial outlook is increasing variable compensation expenses, which will impact costs in Q3. Says seeing cost impacts from continuing inflationary pressures and from supply chain mitigation actions related to industry-wide shortages. Says due to the pull-in of cost reductions in Q2, expects more modest front-end cost reductions in Q3 on a sequential basis. Says a higher mix of NAND revenue in our consolidated total will affect consolidated gross margin, as DRAM gross margins are substantially higher than our NAND gross margins.

16:38 EDT WeWork appoints SoftBank partner to board, names Sandeep Mathrani chairman - WeWork (WE) announced that Saurabh Jalan, partner at SoftBank Group (SFTBY), has joined WeWork's board of directors. Jalan will bring his experience working with global technology platforms to WeWork's board of directors. Additionally, the board has appointed WeWork CEO Sandeep Mathrani to the position of chairman of the board; Mathrani has served on the board since he was appointed CEO of WeWork in February 2020.

16:34 EDT Hess Midstream Partners signs accretive $400M sponsor unit repurchase - Hess Midstream announced the execution of a definitive agreement providing for the repurchase of $400M in Class B units by its subsidiary, Hess Midstream Operations LP, from affiliates of Hess Corporation and Global Infrastructure Partners, Hess Midstream's sponsors. The terms of the proposed unit repurchase transaction were unanimously approved by the Board of Directors of Hess Midstream's general partner, based on the unanimous approval and recommendation of its conflicts committee composed solely of independent directors. "With today's announcement, we again demonstrate both our financial flexibility and our commitment to consistent and ongoing return of capital to our shareholders," said Jonathan Stein, CFO of Hess Midstream. "The unit repurchase transaction is expected to optimize our capital structure to our targeted 3.0x Debt/Adjusted EBITDA for full year 2022 and provide significant and immediate accretion to our shareholders. In addition, we expect to continue to have financial flexibility, including ongoing free cash flow after distributions, to allow for potential further incremental return of capital to shareholders in 2022."

16:31 EDT Core Scientific sees FY22 hashrate of 40-42 EH/s - In 2022, the company "expects to achieve total hashrate of between 40 EH/s and 42 EH/s, with total power between 1,200 MW and 1,300 MW."

16:28 EDT Fluor gets final notice for Interstate 35E Phase 2 Project in Dallas - Fluor "announced that Lone Star Constructors, its joint venture with Austin Bridge & Road, has been granted final notice-to-proceed by the Texas Department of Transportation that releases the full contract value and positions the venture for construction to begin on Phase 2 in summer of 2022 for the Interstate 35E project from Interstate 635 in Dallas to the Denton County line in Carrollton, Texas. The Fluor-led team was initially awarded the contract for this project in July 2021. Fluor booked its share of the approximately $640 million contract value in the third quarter of 2021."

16:20 EDT 3D Systems enters AM joint venture with Saudi Arabian Industrial Investments - 3D Systems and the Saudi Arabian Industrial Investments have signed an agreement intended to expand the use of additive manufacturing, or AM, within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The announcement was made during a ceremony in Riyadh on March 29. The purpose of the new joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom's 'Vision 2030,' which is focused on diversification of the economy and long-term sustainability. The Center for Innovation and Additive Manufacturing will initially focus on energy, with planned expansions into other industrial sectors as well as healthcare solutions. The joint venture follows a selection process in which 3D Systems was chosen due to its breadth of additive technology as well as depth of application expertise. Modeled upon 3D Systems' application development and advanced manufacturing sites located in Littleton, Colorado, and Leuven, Belgium, the new facility is expected to open in late 2022 and is meant to include a breadth of plastic and metal 3D printing technologies as well as 3D Systems application engineers who bring deep industry-specific expertise.

16:17 EDT MillerKnoll jumps 6% to $35.00 after reporting Q3 results, Q4 guidance

16:16 EDT Norfolk Southern announces new $10B share repurchase program - Norfolk Southern announced that its Board of Directors has authorized a new program for the repurchase of up to $10B of its common stock beginning April 1. The company's current program will be terminated on March 31.

16:14 EDT Micron higher by 3.6% following Q2 earnings report

16:10 EDT Verso receives regulatory approval for merger with BillerudKorsnas AB - Verso announced it has received necessary approvals from the Nuclear Regulatory Commission and the Public Service Commission of Wisconsin to complete its previously announced merger with BillerudKorsnas AB. Verso has now received all regulatory approvals necessary to complete the merger. The transaction is expected to close on March 31.

16:08 EDT MillerKnoll says not fulfilling or accepting new orders from Russia, Belarus - The company said, "We are closely monitoring the tragic war in Ukraine, and we have centered our response on humanitarian efforts. Our Foundation is matching donations from our employees, dealers, and suppliers to organizations who are providing assistance on the ground. MillerKnoll is not fulfilling any existing orders or accepting new orders from Russia or Belarus at this time. As a safety measure, we have also stopped taking new orders and fulfilling orders in Ukraine. This region represents a small portion of our International Contract business. FY21 annual revenue was approximately $10 million. While we do not have manufacturing facilities or offices in the region, we have historically sold products to two dealers in Ukraine, two in Russia, and two in Belarus."

16:04 EDT VLNS Stock trading halted, news pending

15:21 EDT Activision Blizzard settlement with EEOC to be approved by federal court - This morning the federal court indicated it would approve Activision Blizzard's settlement with the EEOC. That settlement paves the way to compensate and make amends to eligible claimants. As part of the agreement with the EEOC, Activision agreed to: Create an $18 million fund to compensate eligible claimants. Continue enhancing policies, practices, and training to prevent harassment and discrimination in the workplace, including by implementing an expanded performance-review system. Engage a neutral, third-party equal employment opportunity consultant - a non-employee who must be approved by the EEOC - who will provide ongoing oversight of the company's compliance with the agreement. This independent consultant's findings will be reported directly to the EEOC and Activision Blizzard's board of directors. Hire an internal EEO coordinator with relevant experience in gender discrimination, harassment, and related retaliation to assist the company. Stacy Jackson began this position on March 16.

15:01 EDT St. Louis Fed chief Bullard's says FOMC 'must now' increase 'policy rates' - James "Jim" Bullard, president and CEO of the Federal Reserve Bank of St. Louis, said in part, in a statement on Tuesday: afternoon . "During the COVID-19 recession, the Federal Open Market Committee or FOMC reduced the target range for the federal funds rate to near zero and began large purchases of U.S. Treasury securities and agency mortgage-backed securities. Although the recession ended nearly two years ago, U.S. monetary policy settings remain set near peak accommodation-with the policy rate only 0.25 percentage points higher now and the size of the Fed's balance sheet at nearly $9T...The FOMC must now follow through with policy rate increases and balance sheet runoff. Otherwise, we risk squandering policy credibility with respect to the 2% inflation target.In March, the FOMC decided to raise the policy rate from near zero with ongoing increases likely to be appropriate. Although the FOMC voted to increase the target range for the federal funds rate by 0.25 percentage points, I advocated an increase of 0.5 percentage points.2 Furthermore, the latest SEP indicated that the median FOMC participant is now projecting an even higher policy rate at the end of this year and the next two years than before. In particular, the median federal funds rate projection for 2022 is 1.9% in the latest SEP (compared with 0.9% in December) and 2.8% for both 2023 and 2024 (compared with 1.6% and 2.1%, respectively, in December). And as noted in the post-meeting statement and in Fed Chair Jerome Powell's press conference, the FOMC expects balance sheet reduction to start at a coming meeting." Reference Link

14:48 EDT TJX announces 13% increase in common stock dividend to 29.5c per share - TJX Companies announced that its board of directors has raised the amount of its quarterly dividend by 13% from the last dividend paid. The board declared a regular quarterly dividend in the amount of 29.5c per share, payable June 2 to shareholders of record on May 12. Ernie Herrman, CEO and President of The TJX Companies, stated, "I am pleased to report that our board of directors has approved a 13% increase in our quarterly dividend. This marks our 25th dividend increase over the last 26 years. Over this period, the company's dividend has grown at a compound annual rate of 21%. In addition, we plan to continue our significant share buyback program, with approximately $2.25 to $2.50 billion of repurchases planned for Fiscal 2023. These actions underscore our confidence in our ability to continue delivering profitable sales and strong cash flow, which enables us to simultaneously reinvest in the growth of the business and return significant value to our shareholders."

13:58 EDT Envista CFO: Investor Day to be focused on longer-term picture - In a presentation earlier at the Piper Sandler Dental Day, Envista CFO Howard Yu said that the "world has changed a bit" since the company last provided FY revenue guidance with its Q4 earnings report. The company plans to provide an update "in the next month or so," but that the upcoming Investor Day is focused on the longer-term picture. Envista shares are down 3.3% to $48.89 in afternoon trading.

13:44 EDT PPL says MA SJC dismissed appeal with prejudice, vacated previous stay - According to a regulatory filing, from PPL Corp: "as previously disclosed, on March 3 the Supreme Judicial Court for the Commonwealth of Massachusetts issued an order granting a stay of a waiver order that the Massachusetts Department of Public Utilities had issued granting a waiver of the MA DPU's jurisdiction over the sale by National Grid USA of its wholly-owned subsidiary, The Narragansett Electric Company, to PPL Rhode Island Holdings, an indirect wholly-owned subsidiary of PPL. On March 25, National Grid and the Attorney General of the commonwealth of Massachusetts filed with the Supreme Judicial Court a Joint Stipulation of Voluntary Dismissal of Appeal and Motion to Lift the Court's March 3, Order of Stay. On March 29, the Supreme Judicial Court issued an order dismissing the appeal with prejudice and vacating the stay that had been previously entered," said the company.

12:59 EDT Army Contracting Command to issue new contract to Kratos UAS with $95M ceiling - Army Contracting Command for the U.S. Army Program Executive Office for Simulation, Training and Instrumentation, in support of the Threat Systems Management Office, intends to issue a new contract to Kratos Unmanned Aerial Systems, or KUAS, on a sole source basis pursuant to only one responsible source who can meet the requirement, according to post to SAM.gov originally published on March 29. This new contract will have a ceiling of $95M, the notice stated. Reference Link

12:03 EDT Intel, Arizona's MCCCD announce new AI incubator lab - Intel and Arizona's Maricopa County Community College District announced a new artificial intelligence incubator lab for students aspiring to land jobs in areas ranging from business to nursing to healthcare and other professions that increasingly draw on AI technology. The new AI incubator lab in Arizona, and the associate degree program it supports, is the first of its kind in the U.S.

12:00 EDT Daily S&P Biotech Bear 3x Shares falls -11.2% - Daily S&P Biotech Bear 3x Shares is down -11.2%, or -$4.03 to $31.99.

12:00 EDT Terran Orbital falls -13.6% - Terran Orbital is down -13.6%, or -$1.61 to $10.19.

12:00 EDT Nielsen rises 20.6% - Nielsen is up 20.6%, or $4.58 to $26.79.

11:35 EDT TuSimple, Loadsmith partner for SAE L4 autonomous technology - TuSimple announced its partnership with Loadsmith to adopt, integrate and scale TuSimple's SAE L4 autonomous technology into their operations. Included within the agreement comes an initial reservation of 350 units of purpose-built SAE Level 4 autonomous trucks for operation on TuSimple's autonomous freight network in 2024.

11:14 EDT IGM Biosciences trading resumes

11:06 EDT Pyxis Oncology, Biosion enter license agreement for BSI-060T - Biosion announced that Biosion and Pyxis Oncology have entered into an agreement under which Pyxis Oncology will be granted an exclusive license to develop and commercialize Biosion's anti-Siglec-15 monoclonal antibody, BSI-060T, world-wide, excluding Greater China. Under the terms of the agreement, Biosion will receive a $10M up-front license fee from Pyxis Oncology. In addition to the up-front payment, Biosion has the potential to receive significant milestone payments for PYX-106, totaling up to $222.5M and single to low double-digit royalties on commercial sales. Pyxis Oncology plans on submitting the IND for PYX-106 to the FDA by the second half of 2022 and initiating a Phase 1 trial shortly thereafter. Under the agreement, Pyxis Oncology has the opportunity to license additional preclinical assets that target anti-Siglec-15 using other approaches to treatment.

11:02 EDT Blue Bird receives order for 30 electric school buses from Modesto City Schools - Blue Bird Corporation has received the single largest order of electric school buses from a school district in its history. Modesto City Schools in California purchased 30 zero-emission school buses. The order enables the school district to rapidly convert nearly 50% of its diesel-powered bus fleet to clean energy.

10:54 EDT L3Harris Technologies announces strategic partnership with Shield Capital - L3Harris Technologiesand venture capital firm Shield Capital announce they have formed a strategic partnership to "foster emerging defense and commercial technologies that address customers' growing requirements for innovative, agile solutions that can be rapidly fielded." "The agreement provides L3Harris access to disruptive innovators for technology transfer, teaming arrangements, direct investments or potential acquisitions and partnered contracts. Working with Shield Capital is part of the company's strategy to leverage third-party capabilities and make calculated investments to address customers' most urgent and difficult national security challenges," the company stated. Christopher Kubasik, Vice Chair and CEO, L3Harris, added: "Through internal and partnered efforts, we are assessing and pursuing the most meaningful solutions that will impact across domains and deliver compounding effects."

10:43 EDT Moderna receives FDA approval for authorization of second COVID vaccine booster - Moderna, announced that it has received approval from the U.S. Food and Drug Administration for its amendment to the emergency use authorization, or EUA, to allow for a second booster dose of its COVID-19 vaccine, mRNA-1273, at the 50 B5g dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise. "Moderna continues to collect and monitor real-world data on its COVID-19 vaccine. Real-world evidence continues to confirm the effectiveness and robust safety profile of the Moderna COVID-19 vaccine. Clinical trials are ongoing for Moderna's Omicron-specific booster, mRNA-1273.529, and a bivalent Omicron-specific booster, mRNA-1273.214," the company stated.

10:39 EDT Willis Lease enters lease agreements with Transportes Aereos Guatemaltecos - Willis Lease Finance announced it has entered into lease agreements with Transportes Aereos Guatemaltecos for four ATR 72-500 aircraft. The five-year deal sees the aircraft overhauled and refurbished, fitted with new Pratt & Whitney Canada PW127M engines. In addition to the aircraft leases, TAG will be included in Willis Lease's ConstantThrust program. Under the agreement, program maintenance and care for the engines is overseen by Willis Lease, including providing spare engines when the need arises.

10:32 EDT Grizzly says Emerita runs 'bait & switch' scheme, stock setup for steep decline - In a recently publish report, Grizzly Research says that it believes Emerita Resources is "running a classic 'bait and switch' scheme, and the stock is setup for a steep decline after the rapid ascent. We carefully examined the operating history of EMO and found that none of their projects have come to fruition. We discovered multiple instances where it seems the company blatantly lied to investors to portray an unrealistic optimistic outlook." "The involvement of Forbes & Manhattan and Stan Bharti is a major red flag to us. Many Bharti-backed companies examine according to our research a pattern of misrepresentation and rapid stock movements that end badly for public shareholders. We believe EMO will be no different," the report reads. "We believe EMO will not be awarded the Aznalcollar Tender regardless of the outcome of the Tender appeal, as they simply lack the resources necessary to win the bid. Similarly, we believe that the IBW project will also fail. When we combine our insights with (Emerita)'s history of taking dilutive financing at steep discounts, we have a hard time seeing public shareholders succeed. We believe (Emerita)'s stock will soon retract to a sub 30 cent level." In morning trading, shares of Emerita Resources have dropped almost 6% to $2.05.Reference Link

10:24 EDT SpiderOak, Lockheed Martin Space enter cybersecurity collaboration - SpiderOak Mission Systems and Lockheed Martin Space's Mission Solutions business are developing and testing a zero-trust cybersecurity platform to secure data across the space data supply chain. The two companies have signed an agreement to field key components of the SpiderOak OrbitSecure platform. Lockheed Martin will use its extensive experience with end-to-end mission operations for orbital satellite systems to support the full integration of the new OrbitSecure technology into practical satellite management. SpiderOak will work with Lockheed Martin in adapting SpiderOak's commercial technology to new uses for potential military and intelligence community satellite operators.

10:18 EDT Ameresco selected as partner in Bristol City Leap project - Ameresco announced that its subsidiary, Ameresco Ltd., has been selected as a partner in the Bristol City Leap project, a 20-year concession to decarbonize the city. In partnership with numerous City of Bristol stakeholders, Ameresco, in collaboration with Vattenfall Heat UK, will work through a unique public private partnership structure to provide services including energy efficiency upgrades, wind and solar services, project financing, long-term operation and maintenance and more. The Bristol City Leap project is intended to operate over a 20-year term, targeting net zero goals through a series of energy and infrastructure investment opportunities, attracting approximately GBP 1 billion of inward investment.

10:01 EDT TD Synnex announces medium-term targets, including revenue growth CAGR 6%-7% - TD SYNNEX (NYSE: SNX), a leading global distributor and solutions aggregator for the IT ecosystem, will host its virtual Investor Day today beginning at 11:00 a.m. EDT. In conjunction with the event, the company is also unveiling its medium-term financial outlook. Over the medium-term, which is defined as the next three to four years, the company expects to achieve: Revenue growth of 6%-7% at a compounded annual growth rate; Total shareholder return of 15%-20% Non-GAAP operating margin of approximately 3%.

10:00 EDT LSB Industries falls -12.3% - LSB Industries is down -12.3%, or -$2.83 to $20.17.

10:00 EDT Epam Systems rises 15.7% - Epam Systems is up 15.7%, or $43.34 to $318.53.

10:00 EDT Nielsen rises 21.5% - Nielsen is up 21.5%, or $4.78 to $26.99.

09:47 EDT Peabody Energy falls -9.1% - Peabody Energy is down -9.1%, or -$2.22 to $22.21.

09:47 EDT Lightning eMotors falls -9.8% - Lightning eMotors is down -9.8%, or -56c to $5.10.

09:47 EDT Ginkgo Bioworks rises 16.2% - Ginkgo Bioworks is up 16.2%, or 60c to $4.34.

09:46 EDT Target Hospitality Corp trading resumes

09:45 EDT Spartan Acquisition III Corp trading resumes

09:42 EDT GameStop trading resumes

09:38 EDT AMC Entertainment trading halted, volatility trading pause

09:36 EDT Target Hospitality Corp trading halted, volatility trading pause

09:25 EDT Gaucho - Buenos Aires acquires domain name Guacho.com - Gaucho - Buenos Aires announces the name change of it web address to Gaucho.com. The company made the strategic decision to revise its existing domain "gauchobuenosaires.com" to gaucho.com because as one of the first things its visitors see, the domain better defines its brand, can increase overall awareness, and reach more customers searching for the common term. The new domain name ads credibility to the brand itself, as well as its website, and may increase click-through rate and boost search traffic.

09:23 EDT Live Current Media announces additional convertible debenture financing - Live Current Media announces that it has closed an additional tranche of convertible debenture financing pursuant to which the Company has received $886,000 and issued a Debenture with a face value of $956,880. This brings the total financing completed by the Company via convertible debt in the past quarter to $3,386,000. The proceeds will be put towards development and marketing of the Kast video streaming platform as per the recently announced merger agreement with Evasyst. The Debenture carries interest of 4% per annum and a term of 24 months. At the option of the holder, the Debenture is convertible into common shares of the Company at $0.34 per share at any time up until maturity and the Company has the right to repay the Debenture at any time until maturity. The Debenture includes a 5-year, three quarter warrant with a $0.60 exercise price.

09:21 EDT Stratasys teams with Lockheed to qualify material for space/aviation parts - Stratasys (SSYS), announced that it is providing the public with baseline material qualification data for Antero 840CN03 filament material in collaboration with Lockheed Martin (LMT) and Metropolitan State University of Denver. The release of this qualification data allows those in the industry to use the material for additively manufactured aerospace parts, such as those on the Orion spacecraft, using Stratasys production-grade 3D printers. "We want to demonstrate a new model for how industry, manufacturers and academia can collaborate to gather and release material qualification data that helps accelerate the adoption of additive manufacturing across the aerospace industry," said Foster Ferguson, Director of Aerospace for Stratasys. Designed for space-ready performance, Antero 840CN03 is a blended and functionalized PEKK-based high-performance, ESD thermoplastic composite material developed specifically for production-grade Stratasys FDM 3D printers that meets ESD performance and NASA outgassing requirements while also exceeding the flame, smoke, and toxicity FST characteristics required for aviation applications.

09:20 EDT Coherus announces multiple near-term anticipated product launches - Coherus BioSciences is hosting a meeting with analysts and investors to present the Company's corporate strategy to build a leading innovative immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. At the meeting, Theresa LaVallee, PhD, Chief Development Officer, is providing an update on the Company's clinical stage immuno-oncology R&D programs. Toripalimab was granted Breakthrough Therapy designation in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC in 2021 as well as in monotherapy in the second or third-line treatment of recurrent or metastatic NPC, and a Biologics License Application for these indications is currently under priority review by the United States Food and Drug Administration with a Prescription Drug User Fee Act target action date of April 30, 2022. Coherus and partner Junshi Biosciences are working closely with the FDA to complete the review process including the scheduling of any required inspections in China. Dr. LaVallee is also presenting details about the potential to pursue additional indications for toripalimab, including through possible expansion of several ongoing pivotal studies into multi-regional clinical trials with enrollment of patients in the United States. Dr. LaVallee and Dr. Sanjay Khare, Senior Vice President of Immuno-oncology R&D, are presenting, for the first time, an overview of Coherus' earlier stage immuno-oncology R&D programs: CHS-006 is being evaluated in an ongoing clinical trial. In 2023, Coherus expects to receive clinical data informing dose-selection and is planning to enroll new patient cohorts in the United States to evaluate CHS-006 + toripalimab for treatment of several solid tumor indications that may include non-small cell lung cancer, small cell lung cancer, esophageal cancer, and hepatocellular carcinoma. Coherus is pursuing two early-stage development candidates designed to improve anti-PD-1 clinical benefit by transforming an unfavorable tumor microenvironment to a more favorable TME. Coherus expects to file investigational new drug applications with the FDA in 2023 for CHS-1000, an antibody targeting ILT4, and in 2024 for CHS-3318, an antibody targeting CCR8. Coherus expects its immuno-oncology R&D investments will lead to ongoing identification of promising pipeline assets and the submission of at least one new IND application for immuno-oncology development candidates per year beginning in 2023. Paul Reider, Chief Commercial Officer, is presenting an overview of the Company's plans for up to four new product launches in the next 15 months. Toripalimab launch readiness is on track and will benefit from the high overlap in customer accounts between UDENYCA and toripalimab. If approved, toripalimab will be the first and only PD-1 inhibitor registered in the United States for the treatment of advanced nasopharyngeal carcinoma. CIMERLI, a Lucentis biosimilar, is under FDA review with a target action date of August 2, 2022. If approved, Coherus is preparing to launch CIMERLITM in the second half of 2022 into the $8B anti VEGF market and to drive adoption among retina specialists that the Company believes will be receptive to using an anti-VEGF biosimilar. The FDA approved Coherus' Humira biosimilar, YUSIMRY, in December 2021, and Coherus plans to launch YUSIMRY in the United States on or after July 1, 2023. With projected 2022 U.S. Humira net sales of more than $18 billion, the Humira market represents a uniquely large and attractive opportunity. Coherus has made significant investments in manufacturing capacity and expects to be a low-cost, high-volume adalimumab manufacturer. Coherus expects this investment to result in launch-year manufacturing capacity of approximately 1.2 million units, or about 10% of the overall adalimumab market, equal to the Company's target market share. After additional YUSIMRY scale-up efforts, the current manufacturing site has the potential to supply as much as 30% of the overall U.S. adalimumab market, three times Coherus' target market share. Coherus is planning a potential 2023 launch, assuming approval by the FDA, of its UDENYCA on-body injector presentation. The UDENYCA OBI would enable Coherus to compete directly against Neulasta Onpro, which has approximately a 50% share of the overall pegfilgrastim market. Coherus believes the on-body segment of the pegfilgrastim market represents a $1 billion market opportunity and that a UDENYCA OBI would generate significant new growth for the UDENYCA franchise in 2023 and beyond.

09:18 EDT AutoZone, Lectron announce retail partnership - Lectron, an electric vehicle charging brand, has entered a retail partnership with AutoZone in a bid to make electric vehicle charging more accessible to consumers. AutoZone now carries a wide selection of Lectron products on its website, including chargers, charging stations, and adapters. Lectron has a reputation for bringing quality and affordability to the EV charging space. The move by AutoZone makes Lectron its most widely available EV charging provider.

09:16 EDT Cboe Global Markets names Tim Lipscomb as Chief Technology Officer - Cboe Global Markets announced two senior executive promotions that will further accelerate the company's growth as it continues to advance on its global expansion strategy. These promotions include the appointments of Tim Lipscomb as Senior Vice President, Chief Technology Officer, and Stephanie Renner as Senior Vice President, International Finance. As Chief Technology Officer, Lipscomb, currently COO of Cboe Europe, will lead Cboe's technology strategy, innovation and integration efforts globally, including overseeing all of Cboe's exchange, data and clearing platforms. In her new role, Renner, currently CFO of Cboe Europe, will lead all of Cboe's non-U.S. finance functions, overseeing the company's Canadian, European and Asia Pacific financial operations, planning, analysis and reporting. Both executives will relocate from London to Kansas City to assume their new positions.

09:14 EDT Edesa Biotech appoints Jennifer Chao to board of directors - Edesa Biotech announced the appointment of Jennifer Chao to the company's Board of Directors. She is the founder of CoreStrategies Management, LLC, which provides corporate and financial consulting to biotech and life sciences companies.

09:11 EDT Milestone commences sales of CompuFlo Epidural at two pain clinics - Milestone Scientific announced that it has commenced sales of the CompuFlo Epidural disposables at the Cypress Surgery Center in Santa Maria, California and the Galileo Surgery Center in San Luis Obispo. Both of these prominent pain management practices are located in California and owned by Pain Management Specialists. Arjan Haverhals, CEO and president of Milestone Scientific, stated, "We continue to expand sales of our CompuFlo Epidural system within pain clinics across the U.S. The selection of our technology by these two clinics follows successful evaluation, reinforcing the safety, economic and efficiency benefits, as well as the improved patient experience."

09:11 EDT CVD Equipment gets CVD/ALD system order from Georgia Institute of Technology - CVD Equipment announced that it has received a CVD/ALD system order from Georgia Institute of Technology. This system will be used to coat powders with high performance nanomaterials for electric vehicle battery applications. CVD Equipment plans to design and manufacture the system as a standard product platform to coat powders for Research and Development which can be scaled for pilot production. This system features a tumbling bed to coat powders uniformly and will have the capability of both chemical vapor deposition and atomic layer deposition processes. ALD is a thin film deposition process that allows for atomic layer thickness resolution, excellent conformity of high aspect ratio surfaces, and pinhole-free layers. This is achieved by the sequential formation of atomic layers in a self-limiting reaction. As EV battery technology moves from R&D to production, CVD Equipment Corporation is well positioned to support its customers with turnkey equipment solutions enabling cost effective manufacturing of EV electrode materials. Coating powders with carbon, silicon nanowires, and emerging nanomaterials provide opportunities to improve battery performance and decrease costs per kWh. "CVD is pleased to receive this order and we are excited to have been awarded this order as we continue to focus on growing our market presence in the lithium-ion battery and electric vehicle emerging markets," said Emmanuel Lakios, President and CEO of CVD Equipment Corporation.

09:09 EDT VerifyMe announces largest brand protection order to date - VerifyMe announced that it has received a follow-on order for approximately five million VerifyMe technology-enabled product labels from a cannabis related client. The client has added additional brand protection features enhancing product security on this new order, scheduled for delivery in the second quarter. Dynamic VerifyMe codes allow consumers to authenticate the product and receive detailed product-specific information using their smartphones.

09:09 EDT Stratasys teams with Lockheed to qualify material for spaceaviation parts - Stratasys (SSYS), announced that it is providing the public with baseline material qualification data for Antero 840CN03 filament material in collaboration with Lockheed Martin (LMT) and Metropolitan State University of Denver. The release of this qualification data allows those in the industry to use the material for additively manufactured aerospace parts, such as those on the Orion spacecraft, using Stratasys production-grade 3D printers. "We want to demonstrate a new model for how industry, manufacturers and academia can collaborate to gather and release material qualification data that helps accelerate the adoption of additive manufacturing across the aerospace industry," said Foster Ferguson, Director of Aerospace for Stratasys. Designed for space-ready performance, Antero 840CN03 is a blended and functionalized PEKK-based high-performance, ESD thermoplastic composite material developed specifically for production-grade Stratasys FDM 3D printers that meets ESD performance and NASA outgassing requirements while also exceeding the flame, smoke, and toxicity FST characteristics required for aviation applications.

09:08 EDT Robinhood extending trading hours to 7 a.m. to 8 p.m ET - Robinhood stated in a post to its corporate blog: Robinhood was built to revolutionize the markets and bring more people into our financial system. That's why Robinhood is working towards offering 24/7 investing - giving customers unprecedented access to the financial markets. In the future, when not beholden to traditional hours, retail investors will be able to invest more on their own terms and timelines, regardless of time of day or week. As an important step towards 24/7 equities investing, we're launching new extended hours that will allow customers to trade from 7 a.m. to 8 p.m. ET. By expanding pre-market trading to 7 a.m. from 9 a.m. ET and after-hours trading to 8 p.m. ET, we're adding an extra four hours for orders to be filled." Reference Link

09:08 EDT Snowflake extends relationship with AWS - Snowflake (SNOW) announced an extension of its relationship with Amazon Web Services (AMZN), or AWS, to improve demand forecasting and delivery for the retail and consumer packaged goods industries. This latest development will offer customers the ability to receive Amazon purchase order data and leverage product demand forecast data generated by Amazon Forecast within Snowflake's Retail Data Cloud.

09:06 EDT Converge Technology appoints Richard Lecoutre as CFO - Converge Technology Solutions is pleased to announce the appointment of Richard Lecoutre to the Company's Senior Leadership team as Chief Financial Officer. Richard is currently serving as Finance Director at Softcat PLC where he is responsible for all finance operations.

09:04 EDT Turning Point Therapeutics appoints Sun as incoming General Counsel - Turning Point Therapeutics (TPTX) announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics (SRNE).

09:03 EDT Information Services acquires Agreemint, terms undisclosed - Information Services said it has acquired automated contracting solution Agreemint from its founders. Terms were not disclosed. The AI-powered contracting platform brings new capabilities to the ISG GovernX vendor compliance and risk management solution and will be used by ISG to add value to future platform solutions now in development.

09:03 EDT Chicken Soup for the Soul streaming service app premieres on Vizio - Crackle Plus announced the Chicken Soup for the Soul streaming service application is now available on VIZIO. The streaming service will offer thousands of hours of content, including exclusive programming from Kin and Chicken Soup for the Soul original series like Smart Home Nation.

09:01 EDT Muscle Maker's Pokemoto division expands in Rhode Island - Muscle Maker, the parent company of Muscle Maker Grill restaurants, Pokemoto Hawaiian Poke and SuperFit Foods meal prep, announced the signing of five new Pokemoto franchise agreements for Rhode Island. The five additional franchise agreements will bring the total Pokemoto eateries count to six in Rhode Island; a franchise location is currently operating in Providence, Rhode Island. "Pokemoto is in growth mode and these five new franchise agreements brings us to 37 total agreements signed since November 2021. When these units are fully implemented, along with previously opened locations in Virginia, Maryland and Florida, this will represent a 338% growth rate since the acquisition of Pokemoto in May 2021," said Michael Roper, CEO of Muscle Maker and Pokemoto. Roper continued, "Once opened, the five additional units will bolster our presence in the Rhode Island market, making us the largest Hawaiian poke player in the state." Roper continued, "Millennials account for 27% of the population in Rhode Island which is no surprise with the ocean state being home to higher education institutions such as Brown University, Providence College, Bryant University and the University of Rhode Island. Millennials and Gen-Zs are a demographic focal point for our real estate team and the Rhode Island market checks that box for us."

08:46 EDT Revive Therapeutics provides update on Phase 3 trial for bucillamine in COVID-19 - Revive Therapeutics provides an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. In collaboration with Delta Health, the Study is targeting clinicals sites operated by MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 clinical research sites and over 6000 in-patient hospital beds. As previously mentioned, the Company has selected 13 clinical research sites to complete enrollment of the Study. The Company now expects to complete full enrollment in Q2-2022 and to also submit the Study data for 800 subjects to the data safety monitoring board to seek DSMB approval to proceed with an Emergency Use Authorization application to the Food and Drug Administration. The Company is preparing its regulatory package for submission to the FDA and international regulatory authorities for drug approvals.

08:40 EDT Energy Transfer and ENN in 20-year LNG SPA s related to Lake Charles project - Energy Transfer NN Natural Gas and ENN Energy Holdings announced that ENN NG and ENN Energy have entered into LNG Sale and Purchase Agreements with Energy Transfer LNG Export, a subsidiary of Energy Transfer related to its Lake Charles LNG project. Under the two SPAs, ET LNG is expected to supply 1.8M tons of LNG to ENN NG, and 0.9M tons of LNG to ENN Energy, per annum on a free-on-board FOB basis. The purchase price is indexed to the Henry Hub benchmark plus a fixed liquefaction charge. Both SPAs are for a term of 20 years, and first deliveries are expected to commence as early as 2026. The SPAs will become fully effective upon the satisfaction of the conditions precedent by ET LNG, including reaching FID. "The signing of these long-term SPAs will further enrich ENN's LNG resources, expand resource supply channels, and improve ENN's natural gas supply capacity to meet the rapidly growing natural gas demand in the domestic market," said Zheng Hongtao, President of ENN NG and Vice Chairman of the Board of Directors of ENN Energy Holdings. "It also provides our customers with better resources and services, ensures natural gas supply nationwide, and contributes to the low-carbon transformation of energy structure." "We are very pleased to have ENN as a customer. The execution of these two SPAs represents a significant event in moving the Lake Charles LNG project towards FID. We are experiencing strong demand for long-term offtake contracts for Lake Charles LNG and we are optimistic that we will be in a position to take a positive FID by year end," said Tom Mason, President of ET LNG. "The Lake Charles LNG project is expected to be financed primarily through infrastructure funds and strategic partners, with Lake Charles LNG retaining an equity stake and operatorship of the liquefaction facility."

08:39 EDT Exela Technologies closes revolving loan exchange, prepayment agreement - Exela Technologies announced that certain of its subsidiaries closed a Revolving Loan Exchange and Prepayment Agreement with the financial institutions acting as revolving lenders under its First Lien Credit Agreement dated as of July 12, 2017. All of the amounts outstanding under the revolving facility were prepaid with $50 million of cash and the remainder exchanged for $50 million of 11.500% First-Priority Senior Secured Notes due 2026. As a result, there are no further senior debt maturities in 2022. The closing of the revolver is one of the last steps in the initiative to strengthen the balance sheet announced on September 30, 2021. Balance Sheet Initiatives: On September 30, 2021, Exela announced plans to deploy over $400 million of capital to significantly reduce debt; Completed the exchange offer of 2023 Senior Secured Notes and Term Loans into 2026 Senior Secured Notes on December 9, 2021; Listed a 6% Convertible Preferred Stock on Nasdaq on March 22, 2022; Prepaid the revolving loan due July 2022. Strategic Initiatives: Settled the Appraisal Action on December 31, 2021, with $40 million paid as of March 16, 2022; Purchased existing Irish headquarters on February 8, 2022; Acquired Corduro a payment as a service platform, on March 14, 2022; Invested in leadership talent: President of Healthcare Solutions announced on March 16, 2022 along with senior hires in Public Sector, F&A services, Data Science Consulting and SMB business management over the past several months; Invested in UBERDOC, a leading patient access and price transparency firm, on March 25, 2022; As of March 15, 2022, the Company has deployed $601 million including cash and new borrowings.

08:37 EDT Soleno Therapeutics announces pricing of $15M underwritten public offering - Soleno Therapeutics announced the pricing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of $0.25 per share and, for certain investors, in lieu of common stock, pre-funded warrants to purchase 20,000,000 shares of its common stock at a public offering price of $0.24 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. Each share of common stock or pre-funded warrant is being sold together with one, immediately exercisable common warrant with a five year term to purchase one share of common stock at an exercise price of $0.30 per share. The aggregate gross proceeds of the offering are expected to be approximately $14.8 million, before deducting the underwriting discount and other estimated offering expenses, and assuming that no pre-funded warrants are immediately exercised. All shares of common stock, and accompanying common warrants, and pre-funded warrants, and accompanying common warrants, to be sold in the offering will be offered by Soleno. The closing of the offering is expected to occur on or about March 31, 2022, subject to the satisfaction of customary closing conditions. Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Laidlaw & Company is acting as co-manager for the offering. Soleno intends to use the net proceeds from this offering to fund its current research and development efforts primarily focused on advancing its lead candidate, DCCR tablets for the treatment of Prader-Willi Syndrome, and to provide for general corporate purposes, which may include working capital, capital expenditures, other clinical trials, other corporate expenses and acquisitions of complementary products, technologies or businesses, though the company does not have agreements or commitments for any specific acquisitions at this time.

08:35 EDT Bridgeline Digital announces new deal with leading sports retailer - Bridgeline Digital announced that one of the largest lifestyle retailers in Asia has selected Bridgeline's site search to power the new eCommerce site for their sports retail brand with over 250 locations. This is Bridgeline's third international win with a sports retailer in the last 6 months. The site search software's NLP capabilities are a key component of the brand's conversion strategy as it allows for distinct differentiation between brand and product variation within an industry with large catalogs of sports products. Bridgeline will provide search pages, category pages, filters, autocomplete, and product recommendation features for the new website. CEO of Bridgeline, Ari Kahn says, "We look forward to working alongside our retail partner to grow their revenue online. I know Bridgeline's dedication to our customers' success is the driving factor in our partner's decision to select us for a key role in their conversion strategy."

08:33 EDT Galecto compeltes enrollment in Phase 1b/2a GULLIVER-2 trial - Galecto announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part Phase 1b/2a trial of GB1211, GULLIVER-2, in liver cirrhosis. Part 1 of the GULLIVER-2 trial, which was designed to measure the pharmacokinetics of GB1211 in patients with moderate hepatic impairment as compared to healthy volunteers, was completed in December 2021. GB1211 was found to be well-tolerated with no drug-related serious adverse events. Part 2 of the trial is a randomized, double-blind, placebo-controlled cohort in 30 patients with liver cirrhosis and moderate hepatic impairment. This part of the trial is designed to observe the safety and tolerability of GB1211 over 12 weeks while also measuring fibrosis biomarkers, hepatic function, inflammation, and coagulation parameters, as well as detecting fibrosis using transient elastography ultrasound. Part 3 of the trial is an open-label cohort in 6 patients with severe hepatic impairment and 6 matched healthy volunteers that is designed to examine the pharmacokinetics and safety and tolerability of GB1211. "With Part 1 of the trial completed with encouraging initial safety findings and favorable interim exposure data, we are pleased to take another step forward in this important trial of our oral galectin-3 inhibitor, GB1211," said Dr. Hans Schambye, President and Chief Executive Officer of Galecto. "Galectin-3 plays an important role in fibrosis development in the liver, and we have demonstrated GB1211 to be effective in protecting the liver cells and reducing fibrosis in animal liver models. As scientific advances for the treatment of liver cirrhosis have been very limited, galectin-3 inhibition may offer a new therapeutic possibility for patients with liver cirrhosis and related liver diseases. We look forward to presenting top-line results from the GULLIVER-2 trial in the fourth quarter of this year."

08:33 EDT SharpLink Gaming announces update on C4 integration with NASCAR.com - SharpLink Gaming reported that the Company's integrated C4 solution resulted in a measurable improvement in the conversion of NASCAR.com fans to sports betting depositors with BetMGM for the first five weeks of the 2022 NASCAR racing season. Currently, SharpLink is featuring a BetMGM bet slip module on NASCAR.com's home page that incorporates C4 bet recommendation algorithms in states where online sports betting has been legalized. Once a NASCAR fan clicks on the bet slip, a BetMGM promotional offer is provided to the potential bettor. When comparing fan engagement metrics for the first five weeks of the 2022 NASCAR racing season to the entire 2021 racing season averages, the results reflect that: The percentage of NASCAR fans who engaged with promotional offer was 9.2%; The percentage of NASCAR fans who registered with BetMGM after landing increased 72%; The percentage of NASCAR fans who deposited with BetMGM after landing was 152% higher; and The percentage of NASCAR fans who became qualified depositors with BetMGM rose 225%.

08:32 EDT ClearSign Combustion receives initial engineering order from large refiner - ClearSign Technologies announced that it has received an initial engineering order from a large independent national refiner as the first phase of a project to retrofit two process heaters for a total of twenty ClearSign Core burners in one of their California refineries. Similar to other announced process burner projects, this project will consist of multiple phases. The first is this order, which consists of engineering, drafting and CFD, or Computational Fluid Dynamics, modelling of ClearSign Core burners operating in the destination heaters. The following phases of this project are expected to include a physical "first article" full size burner demonstration, then the supply of twenty burners to be installed in the California refinery heaters.

08:31 EDT Aptevo Therapeutics announces patient in AML trial receives transplant - Aptevo Therapeutics announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, has received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing significant reduction in bone marrow blasts. This follows the company's previous announcement that a patient receiving combination therapy is also moving to transplant after one cycle of therapy. APVO436 is currently being evaluated in a Phase 1b expansion trial for adult patients with AML in a multi-center, multi-cohort study of up to 90 patients who will receive either APVO436 in combination with standard of care chemotherapies or as monotherapy. In 2021, the company announced results from its Phase 1b dose escalation trial in patients with both AML and myelodysplastic syndrome or MDS. Results showed that APVO436 exhibited a favorable safety profile with acceptable tolerability and generally manageable drug-related adverse events. Clinical activity was also observed in 11 of 40 patients in the dose escalation part of the study and reported at the American Society of Hematology 2021. This included two complete remissions in patients with AML and three complete marrow responses in patients with MDS.

08:28 EDT Holloway Wealth Management to join ARS Wealth Advisors - Focus Financial Partners announced that it has entered into a definitive agreement under which Holloway Wealth Management, a registered investment advisor based in Gainesville, FL, will join Focus partner firm ARS Wealth Advisors Group, located in St Petersburg, FL. The transaction is expected to close in the second quarter of this year, subject to customary closing conditions. Founded in 2005 by Sam Holloway, Holloway is a fee-based firm that offers comprehensive wealth and investment management services to high net worth professionals, business owners, retirees and their families, primarily in the Gainesville area. Holloway also provides financial planning and portfolio management services to physicians and professors associated with the University of Florida.

08:24 EDT Telus Health acquires Sprout Wellness Solutions - TELUS Health announced it has acquired Sprout Wellness Solutions, a holistic digital health and wellness solution designed to educate, engage and inspire people to improve their health through behaviour change. The solution will be available as part of the TELUS Health suite of services for Canadian employers to empower their employees, through their benefits plan, to live healthier lives. Built using machine learning and cognitive behavioural science, the Sprout platform encourages, measures, and rewards healthy behaviours through: Real-time health risk assessment; Wearable device integrations and activity tracking; Engaging health and wellness content; Dynamic goals, gamified challenges, and more. As an early investor in Sprout since 2015, TELUS recognized the positive influence the innovative health solution had on overall health and wellness, helping employees to shift their mindset to more proactively focus on improving their overall health and happiness. As organizations increasingly seek to embrace more digital well-being empowerment tools for their team members, this acquisition allows TELUS Health to deliver a broader suite of options to complement its established services such as virtual care, virtual pharmacy, and medical and mental health clinics to support Canada's workforce at every step of their health journey. Sprout will continue to be available for all its current customers. Over the coming months, TELUS Health will integrate Sprout Wellness Solutions into its Virtual Care service, making it available as a value-added solution to clients nationally in English and French.

08:21 EDT Splash Beverage announces agreement with Northern Eagle Beverage - Splash Beverage announced an agreement with New Jersey-based AB-ONE distributor Northern Eagle Beverage to distribute SALT Tequila, Copa di Vino wines by the glass, and Pulpoloco Sangria to New Jersey's Bergen, Hudson, Essex and Passaic Counties. Robert Nistico, CEO of Splash Beverage Group commented, "This is another home run distribution agreement for Splash. Our relationship with InBev's AB ONE, the owner of Budweiser, continues to pay dividends for us as more and more high-volume distributors take note of the credibility that comes from our relationship with AB-ONE. New Jersey's Northern Eagle Beverage Company puts our three premium products on the shelves in 4 highly populated NJ counties. In fact, Bergen County is the number one most populated county in NJ and Essex is the second highest. Both Hudson and Passaic Counties are in the top 10, and it's worth noting that NJ is the most densely populated state in the US, so our products will be put in front of many, many new eyeballs which translates to more revenue."

08:19 EDT Dycom Industries appoints Sabater as director - Dycom Industries announced the appointment of Carmen Sabater as a director. Sabater is a Certified Public Accountant and currently serves as the Chief Financial Officer of Quirch Foods Parent. The appointment, effective March 28, 2022, is for a term extending until the Company's 2022 Annual Meeting of Shareholders.

08:18 EDT Augmedix appoints Febbo to board of directors - Augmedix (AUGX) announced that William Febbo, Chief Executive Officer and Director of OptimizeRx (OPRX), has joined its board of directors, effective March 28, 2022. "We are extremely pleased to welcome Will to our board and leverage his depth of experience in building and managing technology and healthcare companies," said Manny Krakaris, Chief Executive Officer at Augmedix. "We believe his experience in successfully leading OptimizeRx's growth and expansion will bring a valuable perspective as we continue on our clear path to unlock the large market opportunity ahead."

08:17 EDT Grove completes initial transactions in program to repurchase up to 1M shares - Grove announced that it has completed the first stage of its previously authorized program to repurchase up to 1 million shares of its outstanding common stock through both the use of the Company's 10b5-1 plan and privately negotiated transactions. The Company repurchased 467,765 shares at an average cost of approximately $4.22 per common share or $1,974,896. These repurchases were made as part of the company's repurchase program, which was announced on October 19, 2021. Grove will continue to review the authorized program and may repurchase up to an additional 500,000 shares.

08:15 EDT Bandwidth appoints Sandy Preizler as Chief Revenue Officer - Bandwidth (BAND) announced that Sandy Preizler will be joining the company in the newly created position of Chief Revenue Officer, or CRO, effective April 18. In his 25-year career, Preizler consistently exceeded revenue and profitability goals for billion-dollar cloud and software portfolios at NCR (NCR), Avaya (AVYA), Cisco (CSCO) and Symbol Technologies by building strong teams, developing new markets, launching new channel strategies and growing customer partnerships-from small and medium businesses to the largest global enterprises. Earlier, Preizler had similar accomplishments as Worldwide Head of Sales for Avaya's Service Provider business-growing revenue to $1.1B-and as Worldwide Head of Channels and Distribution at Symbol Technologies, where he led $1.2B in revenue via 40 global distributors, 10,000 reselling partners and 300 independent software vendor partners. He began his career at Cisco, where he was ranked No. 1 U.S. channel sales director two years in a row and also grew bookings 25% from flat growth the year before in the Service Provider business across EMEA.

08:14 EDT Lantheus collaborates with Novartis to include PYLARIFY in trials with Pluvicto - Lantheus (LNTH) announced a strategic collaboration with Novartis (NVS) to include PYLARIFY in prostate cancer clinical trials with Pluvicto. "The FDA-approval of Novartis' Pluvicto brings hope to patients and is an exciting advancement in the field of radiopharmaceutical oncology," said Mary Anne Heino, President and CEO of Lantheus. "We look forward to collaborating to further explore how PSMA PET imaging agents, like PYLARIFY, may aid in increasing accessibility to PSMA-targeted therapeutics. As always, our goal is to Find, Fight and Follow serious medical conditions and improve patient outcomes." PYLARIFY, approved by the FDA in May 2021, is the first commercially and widely available prostate-specific membrane antigen PET imaging agent. The collaboration with Novartis directly aligns with Lantheus' strategy to advance cancer precision medicine by enabling partners to use PYLARIFY in prostate cancer therapeutic trials. As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus.

08:13 EDT Teledyne Princeton Instruments announces release of LANSIS - Teledyne Princeton Instruments announces the release of LANSIS-a new spectroscopy detector designed specifically for original equipment manufacturers and system integrators. LANSIS cameras represent the latest in CCD array detector technology specifically tailored to OEMs. LANSIS is targeted to instruments with techniques including Raman, optical emissions spectroscopy, fluorescence, and photoluminescence. This camera is ideal for a broad range of clinical and analytical equipment including in-vivo imaging, life science research, cancer detection, pharmaceuticals, drug discovery, material science, failure analysis for microelectronics, and more.

08:12 EDT Verizon, Cisco collaborate to advance autonomous vehicle tech - Cisco (CSCO) and Verizon (VZ) collaborated on a proof of concept demo in Las Vegas, showing that cellular and mobile edge compute technology can enable autonomous driving solutions without the use of costly physical Roadside Units to extend radio signals. The companies said, "The result paves a simpler and more efficient route to powering applications such as autonomous/unmanned last-mile delivery bots and robotaxis in cities like Las Vegas, where public MEC technologies exist. Additionally, cities and roadway operators could create safer roads with C-V2X applications including pedestrian protection, emergency and transit vehicle pre-emption, on and off-ramp protection, and potentially others that involve vehicles approaching intersections with traffic signals...Autonomous features in connected vehicles have always relied on roadside radios to extend the signals vehicles use for low-latency communication with each other and surrounding connected infrastructure. The Cisco and Verizon test proved that Verizon's LTE network and public 5G Edge with AWS Wavelength, together with Cisco Catalyst IR1101 routers in connected infrastructure, can meet the latency thresholds required for autonomous driving applications - replacing the costly roadside radios previously required to meet those needs. By using LTE and edge compute to virtualize the role of the Roadside Units, C-V2X communications proved to be more streamlined - likely to result in improved efficiency and cost effectiveness for municipalities, infrastructure providers, and application developers working with autonomous vehicles. The result demonstrates that connected and autonomous vehicle applications can be deployed today using LTE networks, mobile edge compute, and in-vehicle interfaces deployed by OEMs. These capabilities could lead to safer, less congested roads with current connected and autonomous vehicles, with scalability for future applications hosted at the edge and using LTE and 5G connectivity."

08:11 EDT Altus Power supplies clean electrification solutions to TCC development projects - Trammell Crow Company, TCC and Altus Power announced a strategic partnership to bring Altus Power's clean electrification solutions to TCC's real estate development projects. Under the terms of this multi-year strategic partnership, TCC will engage Altus Power to bring solar power generation, battery storage and electric-vehicle charging to its development portfolio. The initial focus will be 35 million sq. ft. of U.S. industrial assets in TCC's development pipeline. This partnership is expected to generate 300 MW of building-sited, locally generated solar power across the United States over the next three to four years, with battery storage capacity and electric-vehicle charging. TCC and Altus Power plan to expand the partnership to include other assets in the future. "Our partnership with Altus Power will greatly accelerate the integration of clean energy into our properties and we expect it to meaningfully reduce our carbon footprint," said Mike Lafitte, CEO of TCC. "This partnership is directly responsive to our capital partners and occupier clients who expect us to deliver sustainably built real estate." "We are excited about this first-of-its-kind partnership to bring clean electrification to the nation's largest commercial real estate development platform," said Lars Norell, Co-CEO of Altus Power. "This partnership underscores the significant opportunity that is available in the commercial and industrial solar market, and we look forward to working with other real estate owners, developers and occupiers to accelerate their transition to a lower carbon footprint

08:10 EDT Reservoir Media announces deal for catalog of Larry Kusik - Reservoir Media announced a new deal for the catalog of the late lyricist Larry Kusik, best known for his collaborations on theme songs from blockbuster films like The Godfather and Romeo and Juliet. Kusik was a prolific lyricist whose works can be heard in some of the most iconic films released during the 1960s and 1970s. He notably penned the lyrics for "Speak Softly Love," the lyricized theme from 3x-Academy Award-winning film The Godfather, which celebrated its 50th anniversary this month and is widely recognized as one of the greatest films of all time. "Speak Softly Love" won Kusik an ASCAP award and was recorded by several artists, with Andy Williams' version climbing to #34 on Billboard's Hot 100.

08:08 EDT United Airlines Ventures, Oxy Low Carbon Ventures partner with Cemvita Factory - United Airlines Ventures and Oxy Low Carbon Ventures announced a collaboration with Houston-based biotech firm Cemvita Factory to commercialize the production of sustainable aviation fuel intended to be developed through a revolutionary new process using carbon dioxide and synthetic microbes. UAV also announced an equity investment in Cemvita Factory. OLCV, a subsidiary of Occidental (OXY), is a founding investor in Cemvita Factory. SAF is an alternative to jet fuel that uses non-petroleum feedstock and offers lower lifecycle greenhouse gas emissions. United (UAL) has invested in more SAF production than any other airline.

08:07 EDT Tabula Rasa HealthCare renews partnership with Gary and Mary West PACE - Tabula Rasa HealthCare announced a five-year renewal with Gary and Mary West PACE for its CareKinesis PACE Pharmacy and Pharmastar services. Gary and Mary West PACE is a Program of All-inclusive Care for the Elderly, or PACE, in San Marcos, CA, which currently serves over 180 participants who live in North County San Diego. TRHC has partnered with Gary and Mary West PACE since 2018, with the program holding its official opening in October 2019. CareKinesis is a leading PACE pharmacy, which has provided services to PACE organizations since 2011.

08:06 EDT Aeterna Zentaris expects cash to fund operations through 2023 - The Company had $65.3 million in cash and cash equivalents at December 31, 2021.

08:05 EDT ChargePoint, Goldman Sachs partner to introduce new financing solutions - ChargePoint (CHPT) announced a partnership with Goldman Sachs Renewable Power (GS), a long-term investor in clean energy projects. Together, ChargePoint and Goldman Sachs Renewable Power are introducing new tailored financing solutions as part of the ChargePoint as a Service, or CPaaS, product family to reduce upfront costs of EV charging technology for eligible customers. Through this partnership, eligible customers can choose the CPaaS option that best fits their needs, which now includes both financed and turnkey charging. The new financed option enables customers to pay for charging infrastructure as an operational expense, and the turnkey option enables customers offering public charging to host a station at zero cost to them. This partnership will enable customers to implement a superior EV charging solution at no capital expense.

08:03 EDT UroGen Pharma announces FDA clearance of UGN-301 IND - UroGen Pharma announced that the FDA has cleared UroGen's investigational new drug, or IND, application to begin a novel Phase 1 clinical study of the anti-CTLA-4 immunotherapy UGN-301 in patients with recurrent NMIBC. The multi-arm Phase 1 study is expected to start in April and support the development of UGN-301 in high-grade NMIBC.

08:02 EDT VolitionRx annunces global supply agreement with VolitionRx - Heska has announced an exclusive global supply and licensing agreement with VolitionRx to adapt and commercialize the Nu.Q Vet Cancer Screening Test at the point of care for companion animals on Heska's technology. One in four dogs and nearly 50% of dogs over the age of 10 will develop cancer according to the Veterinary Cancer Society. In the U.S. alone, the National Cancer Institute estimates that six million new cancer diagnoses are made in dogs each year. Under the terms of the agreement, Heska intends to adapt and commercialize the Nu.Q Vet Cancer Screening Test for canine screening and monitoring at the point of care exclusively on Heska's analyzers and test platforms.

07:57 EDT Vertical Aerospace jumps 13% to $7.84 per share after VX4 order update

07:53 EDT A2Z Smart Technologies expands pilot program with Evergreen Kosher Market - A2Z Smart Technologies announced the expansion of the pilot program for its Cust2Mate Smart Carts with Evergreen Kosher Market. A2Z's smart carts are now available also at Evergreen's Pomona, New Jersey location and are ready for customer use.

07:49 EDT Lexagene announces advancements to sample preparation cartridge - LexaGene Holdings announced advancements to its sample preparation cartridge for processing complex samples. LexaGene's MiQLab System is designed to process liquid samples from companion animals used in the diagnosis of infections such as urinary tract infections and skin infections. The System, equipped with a MiQLab Bacterial and AMR panel, screens samples for 10 common pathogens and 33 markers for antimicrobial resistance testing. These AMR tests target genes that confer resistance to four classes of first-line therapeutics, namely tetracyclines, beta lactams, sulfa-TMP, and lincosamides. Dr. Jack Regan, LexaGene's CEO and Founder, stated, "Some sample types are easily processed for PCR testing, such as nasal swab samples, whereas other sample types, contain inhibitors that interfere with PCR. To better handle more complex samples, we have recently embedded a new chemistry into our sample preparation cartridge that greatly improves the MiQLab System's ability to process samples that contain a significant percentage of blood, which is a powerful inhibitor of PCR. We are excited about this advancement and believe the new sample preparation cartridge broadens our testing capabilities for companion animals."

07:45 EDT Brookfield Business Partners enters partnership to acquire Nielsen in $16B deal - Brookfield Business Partners (BBU) announced it has entered into a partnership to acquire Nielsen Holdings plc (NLSN) in an all-cash transaction valued at approximately $16B. The companies said, investment highlights include, "Market-leading position. Nielsen is a global leader in audience measurement and a trusted partner to its customers across the entire media ecosystem. The Company has more than 50 years of statistically significant historical data and its scale is unmatched by competitors. Essential service provider. Nielsen's measurement data underpins the $100+ billion video and audio advertising markets and its measurement data is the established industry standard by which video and audio advertising spend transacts. Resilient performance and outlook. The Company's history of consistent growth is driven by its valued offering and longstanding customer relationships. Nielsen's scale and existing market position should support the Company's ability to consistently grow its measurement business. Value creation potential. Nielsen is well positioned to be the leader in cross-media measurement as audience viewership behavior continues to evolve. The development and adoption of Nielsen ONE, Nielsen's cross-media measurement service, will deliver a unified measure of consumer viewership across all media and support the Company's growth strategy." Brookfield will invest approximately $2.65B by way of preferred equity, convertible into 45% of Nielsen's common equity. Brookfield will be actively involved in the Company's governance. Brookfield Business Partners expects to invest approximately $600M, and the balance of Brookfield's investment will be funded from institutional partners. Prior to or following closing, a portion of Brookfield Business Partners' commitment may be syndicated to other institutional investors. The transaction is subject to customary closing conditions and is expected to close in the second half of 2022.

07:41 EDT Starry completes transaction with FirstMark to become publicly traded - Starry became a publicly listed company trading on the New York Stock Exchange with its Class A common stock under the new ticker symbol "STRY." Starry completed the previously announced transaction with FirstMark Horizon Acquisition on March 29 Starry's executive management team and co-founding team were on-hand for the ringing of the opening bell at NYSE on March 29 to celebrate the company's public listing. "Starry was founded with a singular mission: to transform how broadband networks were built so that we could meaningfully improve people's lives with faster, better, more affordable internet access," said Chet Kanojia, co-founder and CEO of Starry.

07:39 EDT Cinedigm closes acquisition of Digital Media Rights for $16.4M - Cinedigm announced that the Company has closed the acquisition of Digital Media Rights, a diversified specialty streaming, advertising, and content distribution company with significant expertise in building audiences for global content in North America. The acquisition closed on March 28, 2022 with a purchase price of $16.4M, payable in installments. The Company paid the first payment of $8M in cash at closing, which was funded with cash on hand. Cinedigm will make additional payments totaling $8.4M in cash or stock at the Company's discretion. Cinedigm will pay annual installment payments of $3M, $3M and $2.4M at 12, 24, and 36 months from the closing date, respectively. Cinedigm expects the acquisition will generate approximately $10M in incremental revenue and $3M in incremental Adjusted EBITDA over the next 12 months. The acquisition of DMR scales up Cinedigm to over 30 streaming channel services, 46,000 films and television episodes and 40 million monthly viewers, while adding approximately 18.5 million social subscribers and 4+ billion views. With the addition of DMR's owned and operated, proprietary channels - specializing in genres ranging from anime and pan-Asian programming, to action, horror, arthouse, romance, kid's series, K-pop and more - the Company will now operate 15 wholly-owned streaming services, which comprises over 50% of Cinedigm's channel portfolio. Given DMR's strong programming and tight demographic alignment with Cinedigm's existing subscription services, the Company plans on leveraging its substantial content library to strengthen both Cinedigm and DMR's existing channels beginning immediately. The combined library will also serve as a cornerstone of the Company's forthcoming umbrella streaming service.

07:36 EDT Monte Rosa Therapeutics sees cash funding operations into late 2024 - Cash, cash equivalents and restricted cash as of December 31, 2021, were $351.4 million, compared to $42.9 million as of December 31, 2020. The company expects that its cash and cash equivalents, including the aggregate net proceeds from the initial public offering, will be sufficient to fund planned operations and capital expenditures into late 2024.

07:32 EDT Enveric Biosciences files provisional patent for more than 100 novel molecules - Enveric Biosciences announces the filing of a provisional patent application based on new discoveries by the Company. The application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible new drug development candidates. The patent application and claimed drug candidates fall into the Company's EVM201 second-generation, psychedelic-derived drug development program, with an initial target indication of cancer-related distress, or CRD, and the potential to be expanded into additional mental health indications.

07:31 EDT Nielsen to be acquired by Evergreen-Brookfield-led consortium for $28 per share

07:31 EDT Nielsen to be acquired by Evergreen, Brookfield-led consortium for $16B

07:29 EDT Nielsen trading halted, news pending

07:27 EDT Osisko Mining announces new results from the Windfall gold project - Osisko Mining provides new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results include 27 intercepts in 8 drill holes and 8 wedges. Osisko Chief Executive Officer John Burzynski commented: "The infill program at Windfall continues to intercept high-grade mineralization. Today's wide headline hole comes from Triple Lynx wireframe 3161 which has another wide zone of 41.4 g/t Au over 9.0 metres. Infill at Underdog is also returning intercepts of over one ounce per tonne over more than two meters."

07:24 EDT Latch CFO Mitchell to resign, appoint Schaeffer as interim CFO, Nakamura as CAO - Latch announced organizational changes to its leadership team. After more than three high-growth years, Garth Mitchell is transitioning out of the Company to pursue other opportunities. Mitchell's last day will be May 10. Effective immediately, Barry Schaeffer will assume Mitchell's duties as interim Chief Financial Officer, CFO. Mitchell will provide advisory services to the Company to facilitate a smooth transition of his duties to Schaeffer. The Company has already begun a search process for a new CFO to support Latch's continued growth. Schaeffer joined Latch as Senior Vice President, Finance in August 2021. Junji Nakamura will also assume a new role as Chief Accounting Officer, CAO. Nakamura joined Latch in April 2020 and most recently served as Senior Vice President, Corporate Controller. As part of this operational evolution, Ali Hussain's duties are also shifting. Hussain will retain his title as Chief Operating Officer but will be stepping down as an executive officer and principal operating officer.

07:20 EDT Antares Pharma announces FDA approval of TLANDO - Antares Pharma announced that the U.S. Food and Drug Administration, FDA, granted final approval for TLANDO, an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Robert Apple, President and Chief Executive Officer of Antares Pharma, commented, "The FDA approval of TLANDO brings to market an oral formulation of testosterone that we believe will prove beneficial to physicians and their patients. We have recently expanded our commercial organization to 108 sales representatives and expect to leverage our relationships with urologists and endocrinologists to drive adoption of TLANDO. This approval also reinforces the opportunity for Antares to continue to drive share gains in the TRT market with both TLANDO and XYOSTED and support our future growth with an expanded commercial portfolio. We look forward to launching TLANDO commercially, which will provide a complementary treatment option to patients and clinicians in the second quarter of this year."

07:17 EDT Renalytix says RAPID biorepository on traxk to exceed 4,000 biospecimens - Renalytix announced the proprietary Renalytix Accelerating Precision medicine In Diabetes biorepository is on track to exceed 4,000 unique patient biospecimens with matching, deidentified electronic health record data in 2022 through the Company's real-world evidence program. RAPID, in combination with unique contracted access to large medical center patient cohorts, enables KidneyIntelX improvements for its bioprognostic methodology and therapeutic response monitoring, and supports expanded regulatory and reimbursement initiatives beginning in calendar year 2022. The RAPID biorepository was initiated in 2020 as a key part of the Renalytix real-world evidence clinical study program to accelerate the development of precision medicine products and services. With over 95% of KidneyIntelX tested patients from multiple real-world evidence programs now consenting for their samples and data to be used, Renalytix expects total biospecimen access for this KidneyIntelX precision medicine platform to exceed 30,000 unique patient specimens by calendar year 2024. The KidneyIntelX RAPID biorepository is expected to continue to grow into one of the largest real-world patient biobanks incorporating current and emerging care standards for kidney disease and diabetes, including use of innovative drug treatments such as SGLT2 inhibitors, GLP1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Recent breakthroughs in therapies, such as SGLT2 inhibitors, GLP1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, for the treatment of kidney and cardiovascular outcomes have intensified the need for precision medicine solutions such as KidneyIntelX to understand individual patient risk and the prediction of early-stage disease progression. KidneyIntelX is the only kidney health platform that has received Breakthrough Device Designation from the U.S. Food and Drug Administration. KidneyIntelX has secured provider agreements with more than 30 state Medicaid programs and is also covered under various commercial insurance programs.

07:15 EDT Zentalis, Caris Life Sciences collaborate to support clinical trials - Zentalis Pharmaceuticals announced a strategic collaboration with Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. Through this partnership, Caris will sequence individuals' complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis' clinical trials. Initially, Caris will assist in the recruiting efforts for Zentalis' clinical trials investigating the Wee1 inhibitor, ZN-c3. Under the terms of the agreement, Zentalis retains full ownership of its therapeutic candidates.

07:14 EDT Eloxx announces therapeutic development award from CF Foundation - Eloxx Pharmaceuticals announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program. This is in addition to the previously announced partial funding of the global clinical trial program. "We are incredibly grateful for this significant level of financial and scientific support from the CF Foundation, which will enable us to build uponour clinical results announced in November 2021 and the potential of ELX-02 to bring forward a treatment for Class 1 CF patients with nonsense mutations," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. "Class 1 CF patients with mutations do not have any available treatment options, and so our ability to work urgently is critical on behalf of patients. Furthermore, this additional award from the CF Foundation extends our cash runway into the second quarter of 2023." The CF Foundation has awarded funding of up to $15.9 million to support the ongoing ELX-02 global Phase 2 clinical program. Following an upfront funding of $7.0 million, the funding will be tranched based on the achievement of certain clinical milestones. Eloxx will pay the CF Foundation royalties tiered to the actual level of funding from the CF Foundation. Patient dosing is ongoing in the expansion arm of the Phase 2 trial, which includes a combination of ELX-02 and Kalydeco, a CFTR protein potentiator. In preclinical studies, Class 1 CF patient organoids had a 2- to 3-fold higher swelling response with a combination of ELX-02 and Kalydeco than with ELX-02 as a monotherapy. Topline results are expected by the end of the first half of 2022. The U.S. Food and Drug Administration has granted Fast Track designation for ELX-02. In addition, ELX-02 has also been granted Orphan Drug Designation for the treatment of CF patients with nonsense mutations by the FDA and orphan medicinal product designation by the European Medicines Agency.

07:14 EDT Passage Bio announces publication of preclinical data on PBKR03 - Passage Bio announced publication of the pre-clinical studies that supported clinical study initiation for PBKR03 gene therapy for infantile Krabbe disease. In the paper reporting these preclinical results, researchers report marked improvements in both disease progression and key biomarkers in large and small animal models of Krabbe disease following a single administration of PBKR03, with no observed dose-limiting toxicities. The paper is published online ahead of print in the May issue of Human Gene Therapy. "The benefits of our strategic collaboration with GTP are apparent when you see the robust preclinical data underpinning our decision to move forward with PBKR03 for infantile Krabbe disease," said Bruce Goldsmith, Ph.D., chief executive officer and president, Passage Bio. "These preclinical studies support our belief that gene replacement with PBKR03 has the potential to provide meaningful clinical benefit by reducing neuronal demyelination and damage to both the central and peripheral nervous systems of children with infantile Krabbe disease. As previously announced, the first child with infantile Krabbe disease has now received PBKR03 in Passage Bio's clinical study - GALax-C - and we look forward to continued enrollment in the initial cohort." For the preclinical studies, the researchers selected animal models in which a spontaneous mutation in the GALC gene recapitulates certain characteristics of human disease in the animal's central and peripheral nervous systems, such as low or no GALC enzyme activity, toxic accumulation of psychosine, and rapid neurological deterioration. Their experiment in mice which was designed to approximate developmental age and disease stage of the intended population with infantile Krabbe disease showed that administration of PBKR03 into the cerebrospinal fluid led to dose-dependent improvements in histopathological, biochemical, and clinical disease signs. Further, in a canine model of Krabbe disease, intra-cisterna magna delivery of the AAV gene therapy resulted in elevated GALC enzyme activity in brain, spinal cord and CSF, reduced psychosine accumulation, and preserved central and peripheral nerve myelination compared to the control group. This led to marked improvements in nerve conduction function, ambulation, and survival. In Passage Bio's clinical trial GALax-C, patients are also administered PBKR03 via ICM.

07:12 EDT Enanta gets FDA fast track designation for once-daily, oral COVID-19 treatment - Enanta Pharmaceuticals announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for EDP-235, its coronavirus 3CL protease inhibitor, also known as the main coronavirus protease, or Mpro specifically designed as a once-daily, oral treatment for COVID-19. "Despite the broad availability of vaccines, there remains a need for highly potent, oral treatments specifically designed to target SARS-CoV-2, a virus that continues to persist and mutate globally. Receiving Fast Track designation from the FDA underscores EDP-235's potential as a once-daily, oral therapeutic for the treatment and prevention of SARS-CoV-2 infection and as another option in the global fight against the ongoing pandemic," said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. "We believe that the profile of EDP-235 positions it as a potential best-in-class antiviral therapeutic and we remain on track to report data from our ongoing Phase 1 study of EDP-235 next quarter. We look forward to working with the FDA to continue to advance EDP-235 as expeditiously as possible."

07:11 EDT Rezolute joins Rare Disease Company Coalition - Rezolute announced that it has joined the Rare Disease Company Coalition. As an alliance of life science companies formed in May of 2021, the Rare Disease Company Coalition is committed to discovering, developing, and delivering rare disease treatments for the patients they collectively serve.

07:08 EDT Taysha gets Canada approval for development of TSHA-102 for Rett syndrome - Taysha Gene Therapies announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application CTA by Health Canada. Sainte-Justine Mother and Child University Hospital Center in Montreal, Quebec, Canada has been selected as the initial clinical site under the direction of Dr. Elsa Rossignol, principal investigator. The company also announced positive preclinical data from IND/CTA-enabling studies including a pharmacology study in the Rett knockout mouse model that assessed the efficacy of TSHA-102 and a Good Laboratory Practices GLP toxicology study of TSHA-102 in nonhuman primates NHPs) that explored biodistribution and mechanism of action, both of which supported authorization of the CTA. "Initiation of clinical development is a significant milestone for the TSHA-102 program and Rett syndrome community," said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha. "Treating Rett syndrome by gene replacement therapy requires an approach that can safely regulate transgene expression in a genotypic manner on a cell-by-cell basis without causing deleterious effects associated with overexpression. TSHA-102's robust preclinical data package supports and validates the safe and controlled regulation of transgene expression using miRARE, a novel miRNA-responsive target sequence exclusively licensed to Taysha and developed by Drs. Sarah Sinnett and Steven Gray1 of UT Southwestern Medical Center. Data from the 6-month non-human primate GLP toxicology study reinforced TSHA-102's favorable safety profile across all dose levels tested including doses up to 4-fold above the presumed clinical starting dose. Data from the IND/CTA-enabling pharmacology study in mouse models of Rett syndrome demonstrated that miRARE regulated transgene expression improved survival, respiratory and motor function assessments across multiple dose levels. We continue to be highly encouraged by the therapeutic potential of TSHA-102." These preclinical safety and efficacy data will be presented at the International Rett Syndrome Foundation IRSF Rett Syndrome Scientific Meeting taking place April 26-27, 2022 in Nashville, Tennessee.

07:06 EDT Vintage Wine Estates partners with Travel + Leisure to launch two wine clubs - Vintage Wine Estates, has partnered with Travel + Leisure Group to launch two wine clubs featuring selections from over 25 wineries throughout Napa, Sonoma, California's Central Coast, Oregon and Washington. Travel + Leisure Wine allows members to select from two exclusive wine clubs for uniquely selected quarterly shipments of renowned wines.

07:04 EDT Spirit Airlines completes terminal move at LaGuardia - Spirit Airlines announced the completion of its terminal move at LaGuardia Airport, or LGA, with all Spirit flights now calling Terminal A home. Over the past year, Spirit maintained a split operation between Terminal C and Terminal A, also known as the Marine Air Terminal. The move has enhanced the LGA Guest experience with all flights now consolidated in one of the most convenient locations at LaGuardia. Additionally, the move also benefits Guests by streamlining Spirit's operation at the airport.

07:03 EDT Gogo announces promotes Sergio Aguirre to COO and other management changes - Gogo announced that Sergio Aguirre will be promoted to President and COO of Gogo effective April 1. Aguirre, who previously served as President of Gogo's Business Aviation Division, will continue to report directly to Gogo Chairman and CEO Oakleigh Thorne. Gogo also announced succession plans for Executive Vice President and General Counsel, Margee Elias, and Executive Vice President and CFO, Barry Rowan, who have separately announced plans to retire. Elias intends to retire by the end of 2022, after 15 years at Gogo. The Company has initiated a search to identify her successor with the assistance of a leading executive search firm. Rowan intends to retire in 2023, shortly after Gogo announces its full-year 2022 results. Jessica Betjemann, Gogo's current Senior Vice President of Finance, Chief Accounting Officer and Treasurer, will succeed Rowan.

07:03 EDT Bausch Health to reduce debt by $200M - Bausch Health Companies announced it will reduce debt by $200M through the pay down of its senior secured term loans on March 31, 2022, using cash generated from operations

07:01 EDT Bristol-Myers annuounces EMA validation of Opdivo in lung cancer treatment - Bristol Myers Squibb announced that the European Medicines Agency, or EMA, has validated its type II variation application for Opdivo, or nivolumab, in combination with chemotherapy for the neoadjuvant treatment of patients with resectable stage IB to IIIA non-small cell lung cancer, or NSCLC, based on results from the CheckMate -816 trial. Validation of the application confirms the submission is complete and begins the EMA's centralized review procedure. In the pivotal CheckMate -816 study, the first positive Phase 3 trial with an immunotherapy in the neoadjuvant setting of NSCLC, three cycles of Opdivo in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival and pathologic complete response versus chemotherapy alone when given before surgery. Based on the results of CheckMate -816, the U.S. FDA approved Opdivo in combination with chemotherapy for the treatment of adult patients with resectable NSCLC in the neoadjuvant setting in March 2022.

06:54 EDT NuScale Power, Spring Valley Acquisition Corp. announce additional $10M PIPE - NuScale Power and Spring Valley Acquisition Corp. announced that SailingStone Capital Partners, a subsidiary of Pickering Energy Partners LP, has committed to a $10M private investment in public equity in furtherance of the NuScale-Spring Valley merger transaction, increasing the total PIPE commitment for this transaction up to $221M. SailingStone provides investment solutions in the global natural resource space with a specific focus on the industrial businesses, commodities and infrastructure assets, which will enable the energy transition. This latest commitment further demonstrates the breadth and strength of investor interest in NuScale's SMR technology and the multifaceted role the company is poised to play in the global energy transition. It also follows NuScale and Spring Valley's announcement in February of the satisfaction of contingencies securing a $30 million PIPE commitment from Samsung C&T Corporation which ensured that, pending satisfaction of remaining closing conditions, the minimum cash threshold for the business combination can be met. The transaction is expected to close in the second quarter of 2022 and is subject to approval by Spring Valley's shareholders as well as other customary closing conditions.

06:52 EDT Tyme Technologies to explore potential strategic options - Tyme Technologies announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value. The company has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor. On January 26, 2022, Tyme announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus for patients with metastatic pancreatic cancer upon learning that the trial sponsor terminated the study arm due to futility. Notwithstanding the discontinuation of its most advanced clinical trial, the company believes there are additional opportunities that could enhance value for Tyne stockholders. Tyne believes that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moelis & Company LLC. The Strategic Planning Committee of the Board will act as a Transaction Committee and will be led by Tyne Board Member Timothy Tyson, who possesses over 35 years of biotechnology and pharmaceutical industry experience, including multiple M&A transactions. There can be no assurance that this process will result in any such transaction, and the company does not intend to disclose additional details unless and until it has entered into a specific transaction.

06:42 EDT AstraZeneca says Ondexxya approved in Japan for reversal of acute major bleeds - Ondexxya has been approved in Japan for patients treated with the Factor Xa, or FXa, inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, AstraZeneca announced. "The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ANNEXA-4 Phase III clinical trial showing Ondexxya rapidly and markedly reversed anti-FXa activity in patients with acute major bleeding. Ondexxya is the first approved medicine in Japan to specifically reverse the anticoagulant effect of FXa inhibitors apixaban, rivaroxaban or edoxaban in patients experiencing a life-threatening or uncontrolled bleed. Japan is also the first country to provide full regulatory approval of Ondexxya for use with all three of the FXa inhibitors currently available," the company stated.

06:36 EDT Transocean acquires minority interest in Ocean Minerals - Transocean announced that it has purchased a minority interest in Ocean Minerals Ltd., a company engaged in the exploration of seabed resources containing metals critical to the growing renewable energy market. Ocean Minerals, through its affiliate, Moana Minerals Limited, was awarded a license by the Cook Islands Seabed Minerals Authority last month for exploration of polymetallic nodules within the application area located in the Cook Islands exclusive economic zone. Critical minerals, such as cobalt, nickel, copper, manganese, and rare earth metals found in the nodules are essential for the production of high-capacity batteries. Transocean is working with Ocean Minerals on the technology and services that will be required to collect nodules from the seabed upon receipt of a production license. The Cook Islands is one of several offshore locations worldwide with large, accessible deposits of nodules containing a high content of these critical minerals. Responsible recovery of the nodules would provide additional supply required to support growing demand.

06:17 EDT Twilio charges three Twilio software engineers with insider trading - The Securities and Exchange Commission on Monday announced insider trading charges against three software engineers employed at Twilio, Inc., a San Francisco-based cloud computing communications company, and four family members and friends for allegedly generating more than $1M in collective profits by insider trading ahead of the company's positive first quarter 2020 earnings announcement on May 6, 2020. According to the SEC's complaint, friends Hari Sure, Lokesh Lagudu and Chotu Pulagam were software engineers at Twilio and had access to various databases relevant to the company's reporting of revenue. As alleged, around March 2020, they learned through the databases that Twilio's customers had increased their usage of the company's products and services in response to health measures taken in light of the Covid-19 pandemic, and concluded in a joint chat that Twilio's stock price would "rise for sure." The SEC's complaint alleges that despite receiving a company policy that prohibited them from insider trading, Sure, Lagudu and Chotu Pulagam knowingly tipped off, or used the brokerage accounts of, their family and close friends - Dileep Kamujula, Sai Nekkalapudi, Abhishek Dharmapurikar and Chetan Pulagam - to trade Twilio options and stock in advance of its May 6, 2020 earnings announcement while in possession of the confidential information concerning customer usage. The SEC's complaint, filed in the Northern District of California, charges each of the defendants with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The U.S. Attorney's Office for the Northern District of California also announced criminal charges against Dileep Kamujula.

06:10 EDT Biodesix announces publication of data from GeneStrat NGS test studies - Biodesix announced that new data were published in the peer-reviewed journal, Diagnostics, in an article titled, "Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants." This peer-reviewed publication further validates the GeneStrat NGS test and the use of multiple classes of tumor markers in circulating free nucleic acid analysis as a surrogate for tumor tissue biopsies. Additionally, Biodesix will present data associated with the GeneStrat ddPCR and NGS blood tests in a poster presentation focused on reporting validation studies of key actionable mutations in NSCLC entitled: Analytic and clinical validation of a new pan-cancer NGS liquid biopsy test for the detection of copy number variations, fusions/exon skipping, somatic variants and indels, at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13. The full abstract can be found on the official AACR website here. Poster presentations will be viewable after April 8th. The company believes that the coupling of highly sensitive, rapid stand-alone droplet digital PCR and the NGS techniques offers more comprehensive blood-based testing support for patients with non-small cell lung cancer, or NSCLC and provides clinically relevant information both before and after targeted treatment of patients with cancer.

06:08 EDT Radware announces $1M deal with major South American conglomerate - Radware announced it expanded its relationship with a major South American conglomerate in a million dollar deal. To support the digital transformation of its portfolio companies, the conglomerate is leveraging Radware's solution to increase its application cybersecurity defenses, expand DDoS protection for its local infrastructure, and add integrated application delivery capabilities. The conglomerate turned to Radware for comprehensive integrated application and network security, including its Attack Mitigation Solution. To protect application availability, the conglomerate increased its investment in Radware's DefensePro DDoS protection. To secure delivery of its web applications and provide API security, the organization deployed Radware's integrated web application firewall.

06:06 EDT JinkoSolar delivers 100GW of solar modules globally - JinkoSolar announced it has delivered 100GW of solar modules globally. JinkoSolar is the first company in history to achieve this milestone. Approximately one out of every ten solar modules installed in the world was produced by JinkoSolar.

06:03 EDT Mattel announces licensing agreement with Universal for Trolls franchise - Mattel announced that it has entered into a multi-year global licensing agreement with Universal Brand Development for DreamWorks Animation's Trolls. The vibrant and joyful animated franchise - teeming with big hearts, hair-raising comedic adventures and award-winning music - Trolls has become one of the most recognized family entertainment brands in the world. Through the agreement, Mattel has the licensing rights to develop a full line of toys for the franchise, including dolls, vehicles, plush, games and more. The collection is expected to launch at retailers around the world in fall 2023. An all-new Trolls film hits theaters in November 2023.

05:31 EDT Envista receives FDA clearance for mandibular nerve tracing feature - Envista announced today the 510(k) FDA clearance of its Assisted Intelligence mandibular nerve tracing feature in its image acquisition and diagnostic software platform DTX Studio Clinic.

05:23 EDT MasterCard, Temenos to collaborate on aiding banks in Request to Pay services - Temenos announced a collaboration with Mastercard that will help banks to accelerate their introduction of Request to Pay services in the UK. This new initiative combines pre-composed solutions on the Temenos Banking Cloud with market-certified Mastercard services, making it easier for financial institutions to introduce Request to Pay services. Request to Pay enables billers to dynamically request and manage the payment for a bill rather than simply sending an invoice.

05:17 EDT Elbit Systems comments on increase in share price - The company said, "Over the last several weeks, there has been a significant increase in the price of the Company's shares. Should such share price levels continue, or further increase, there would be a significant impact on the costs to the Company under its various stock price linked compensation plans for employees."

05:11 EDT Nokia selected by Chunghwa Telecom to enhance 5G network across Taiwan - Nokia (NOK) announced that it has been selected by Chunghwa Telecom (CHT) in a two-year deal to enhance its 5G network across Taiwan's central and southern regions. The deal will see Nokia provide equipment from its latest AirScale portfolio across 4,000 new sites to boost performance and capacity. It will also support CHT's ambition unlocking the potential of 5G, coupled with achieving a lower carbon footprint. Nokia will supply CHT with a wide range of solutions from its AirScale Single RAN equipment portfolio including macro base stations, small cells, 5G Massive MIMO antennas and passive RRH supporting different spectrum bands. The deal will see Nokia continue its long-term vendor partnership with CHT which has been in place from the deployment of 2G networks.